Nick Devoogdt

10.5k citations

155 papers · 8.2k · 2 hit papers · h-index 51

Impact in

Radiology, Nuclear Medicine and Imaging top 0.1%
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
Immunology top 1%
- Immunotherapy and Immune Responses

Papers in

Radiology, Nuclear Medicine and Imaging 114
- Monoclonal and Polyclonal Antibodies Research 99
- Radiopharmaceutical Chemistry and Applications 52
Oncology 74
- HER2/EGFR in Cancer Research 24
- Cancer Immunotherapy and Biomarkers 19
- CAR-T cell therapy research 19
- Peptidase Inhibition and Analysis 18

Co-authors: Tony Lahoutte (63 shared papers)Serge Muyldermans (50 shared papers)Vicky Caveliers (38 shared papers)Catarina Xavier (37 shared papers)Geert Raes (40 shared papers)Matthias D’Huyvetter (37 shared papers)Marleen Keyaerts (31 shared papers)Cécile Vincke (15 shared papers)
Journals: Journal of Nuclear Medicine (16 papers)Molecular Imaging and Biology (8 papers)Frontiers in Immunology (6 papers)Theranostics (6 papers)Biomolecules (5 papers)
Partner nations: Belgium France United States

In The Last Decade

Nick Devoogdt

151 papers receiving 8.1k citations

Nick Devoogdt's Hit Papers

align trajectories log scale

Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells 2016 · 605 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Nature Communications
2015 Journal of Nuclear Medicine

Peers

Countries citing papers authored by Nick Devoogdt

Since Specialization

Citations

This map shows the geographic impact of Nick Devoogdt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Devoogdt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Devoogdt more than expected).

Fields of papers citing papers by Nick Devoogdt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Devoogdt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Devoogdt. The network helps show where Nick Devoogdt may publish in the future.

Co-authors

The 25 scholars most cited alongside Nick Devoogdt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nick Devoogdt Line = papers co-authored together Nick Devoogdt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells Nature Communications ·Charlotte L. Scott, Fang Zheng, Patrick De Baetselier, Liesbet Martens, Yvan Saeys, Sofie De Prijck, Saskia Lippens, Chloé Abels, Steve Schoonooghe, Geert Raes, Nick Devoogdt, Bart N. Lambrecht, Alain Beschin, Martin Guilliams Hit paper breakdown →	2016	605
2	Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma Journal of Nuclear Medicine ·Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Chloé Ackaert, Marian Vanhoeij, François P. Duhoux, Thierry Gevaert, Philippe Simon, Denis Schallier, Christel Fontaine, Ilse Vaneycken, Christian Vanhove, Jacques De Grève, Jan Lamote, Vicky Caveliers, Tony Lahoutte Hit paper breakdown →	2015	341
3	Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy ACS Nano ·Bieke Van de Broek, Nick Devoogdt, Antoine D’Hollander, Hannah-Laura Gijs, Karolien Jans, Liesbet Lagae, Serge Muyldermans, Guido Maes, Gustaaf Borghs	2011	317
4	Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer The FASEB Journal ·Ilse Vaneycken, Nick Devoogdt, Naomi Van Gassen, Cécile Vincke, Catarina Xavier, U. Wernery, Serge Muyldermans, Tony Lahoutte, Vicky Caveliers	2011	265
5	Nanobodies and Their Potential Applications Nanomedicine ·Gholamreza Hassanzadeh‐Ghassabeh, Nick Devoogdt, Pieter De Pauw, Cécile Vincke, Serge Muyldermans	2013	252
6	Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages Cancer Research ·Kiavash Movahedi, Steve Schoonooghe, Damya Laoui, Isabelle Houbracken, Wim Waelput, Karine Breckpot, Luc Bouwens, Tony Lahoutte, Patrick De Baetselier, Geert Raes, Nick Devoogdt, Jo A. Van Ginderachter	2012	244
7	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer Journal of Nuclear Medicine ·Catarina Xavier, Ilse Vaneycken, Matthias D’Huyvetter, Johannes Heemskerk, Marleen Keyaerts, Cécile Vincke, Nick Devoogdt, Serge Muyldermans, Tony Lahoutte, Vicky Caveliers	2013	190
8	Targeted Radionuclide Therapy with A ¹⁷⁷Lu-labeled Anti-HER2 Nanobody Theranostics ·Matthias D’Huyvetter, Cécile Vincke, Catarina Xavier, An Aerts, Nathalie Impens, Sarah Baatout, Hendrik De Raeve, Serge Muyldermans, Vicky Caveliers, Nick Devoogdt, Tony Lahoutte	2014	181
9	Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions Circulation Research ·Alexis Broisat, Sophie Hernot, Jakub Toczek, Jens De Vos, Laurent Riou, Sandrine Martin, Mitra Ahmadi, Nicole M. Thielens, U. Wernery, Vicky Caveliers, Serge Muyldermans, Tony Lahoutte, Daniel Fagret, Cathérine Ghezzi, Nick Devoogdt	2012	157
10	Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging Bioconjugate Chemistry ·Sam Massa, Catarina Xavier, Jens De Vos, Vicky Caveliers, Tony Lahoutte, Serge Muyldermans, Nick Devoogdt	2014	149
11	Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours Journal of Controlled Release ·Pieterjan Debie, Chrystel Lafont, Michel Defrise, Inge Hansen, Danny M. van Willigen, Fijs W. B. van Leeuwen, Rik Gijsbers, Matthias D’Huyvetter, Nick Devoogdt, Tony Lahoutte, Patrice Mollard, Sophie Hernot	2019	146
12	Immunogenicity Risk Profile of Nanobodies Frontiers in Immunology ·Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier, Yann G.‐J. Sterckx, Sofie Denies, Benoı̂t Stijlemans, Yvon Elkrim, Nick Devoogdt, Vicky Caveliers, Tony Lahoutte, Serge Muyldermans, Karine Breckpot, Marleen Keyaerts	2021	143
13	131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment Clinical Cancer Research ·Matthias D’Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszyński, Yann G.‐J. Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael R. Zalutsky, Tony Lahoutte, Nick Devoogdt	2017	141
14	Generation of Single Domain Antibody Fragments Derived from Camelids and Generation of Manifold Constructs Methods in molecular biology ·Cécile Vincke, Carlos Gutiérrez, U. Wernery, Nick Devoogdt, Gholamreza Hassanzadeh‐Ghassabeh, Serge Muyldermans	2012	138
15	PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using ¹⁸F-Radiolabeled Camelid Single-Domain Antibody Fragments Journal of Nuclear Medicine ·Anneleen Blykers, Steve Schoonooghe, Catarina Xavier, Kevin D’hoe, Damya Laoui, Matthias D’Huyvetter, Ilse Vaneycken, Frederik Cleeren, Guy Bormans, Johannes Heemskerk, Geert Raes, Patrick De Baetselier, Tony Lahoutte, Nick Devoogdt, Jo A. Van Ginderachter, Vicky Caveliers	2015	134
16	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle Expert Opinion on Biological Therapy ·Yana Dekempeneer, Marleen Keyaerts, Ahmet Krasniqi, Janik Puttemans, Serge Muyldermans, Tony Lahoutte, Matthias D’Huyvetter, Nick Devoogdt	2016	126
17	Localization, mechanism and reduction of renal retention of technetium‐99m labeled epidermal growth factor receptor‐specific nanobody in mice Contrast Media & Molecular Imaging ·Lea Olive Tchouate Gainkam, Vicky Caveliers, Nick Devoogdt, Christian Vanhove, Catarina Xavier, Otto C. Boerman, Serge Muyldermans, Axel Bossuyt, Tony Lahoutte	2010	120
18	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm International Journal of Molecular Sciences ·Quentin Lecocq, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot	2020	113
19	In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT Journal of Nuclear Medicine ·Ilse Vaneycken, Jochen Govaert, Cécile Vincke, Vicky Caveliers, Tony Lahoutte, Patrick De Baetselier, Geert Raes, Axel Bossuyt, Serge Muyldermans, Nick Devoogdt	2010	109
20	Camelid single-domain antibody-fragment engineering for (pre)clinicalin vivomolecular imaging applications: adjusting the bullet to its target Expert Opinion on Biological Therapy ·Jens De Vos, Nick Devoogdt, Tony Lahoutte, Serge Muyldermans	2013	109

About Nick Devoogdt

Nick Devoogdt is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, Immunology and Biomedical Engineering, having authored 155 papers that have together received 8.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (99 papers), Radiopharmaceutical Chemistry and Applications (52 papers), HER2/EGFR in Cancer Research (24 papers), Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (19 papers), Glycosylation and Glycoproteins Research (19 papers) and Peptidase Inhibition and Analysis (18 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (5.1k citations), Immunology (2.1k citations), Oncology (2.7k citations), Molecular Biology (3.3k citations) and Biomaterials (469 citations). Nick Devoogdt has collaborated with scholars based in Belgium, France and United States. Frequent co-authors include Tony Lahoutte, Serge Muyldermans, Vicky Caveliers, Catarina Xavier, Geert Raes, Matthias D’Huyvetter, Marleen Keyaerts, Cécile Vincke, Patrick De Baetselier and Karine Breckpot. Their work appears in journals such as Journal of Nuclear Medicine, Molecular Imaging and Biology, Frontiers in Immunology, Theranostics and Biomolecules.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Nick Devoogdt

Impact in

Papers in i

In The Last Decade

Nick Devoogdt

Nick Devoogdt's Hit Papers

Peers

Countries citing papers authored by Nick Devoogdt

Fields of papers citing papers by Nick Devoogdt

All Works

About Nick Devoogdt

Explore authors with similar magnitude of impact

Papers in